FOXO1 Cancer Research Results

FOXO1, Forkhead box O1: Click to Expand ⟱
Source:
Type:
FOXO-1 contributes to cellular homeostasis by regulating genes involved in apoptosis, cell cycle arrest, and metabolism.

– In many cancers, FOXO-1 activity can be reduced via genetic or epigenetic mechanisms, altered subcellular localization (e.g., cytoplasmic sequestration following phosphorylation by Akt), or protein degradation.
– This loss of nuclear FOXO-1 activity is often associated with diminished tumor suppressor functions.
– Decreased nuclear FOXO-1 expression or activity correlates with higher tumor grade and poorer prognosis.

– FOXO-1 is a key downstream target of the PI3K/Akt pathway. Hyperactivation of Akt, common in many cancers, leads to FOXO-1 inactivation.
Scientific Papers found: Click to Expand⟱
3433- ALA,    Alpha lipoic acid promotes development of hematopoietic progenitors derived from human embryonic stem cells by antagonizing ROS signals
*ROS↓, *Apoptosis↓, *Hif1a↑, *FOXO1↑, *FOXO3↑, *ATM↑, *SIRT1↑, *SIRT3↑, *CD34↑,
5692- BJ,    Seed oil of Brucea javanica induces apoptosis through the PI3K/Akt signaling pathway in acute lymphocytic leukemia Jurkat cells
- vitro+vivo, AML, NA
Apoptosis↑, Akt↓, P53↑, FOXO1↑, GSK‐3β↑, TumVol↓, QoL↑, BBB↑, OS↑, Dose↝, MMP↓, ROS↑, XIAP↑, Casp9↑, Casp8↑, Casp3↑, cl‑PARP↑, TumCCA↑,
3246- EGCG,    Epigallocatechin gallate suppresses hepatic cholesterol synthesis by targeting SREBP-2 through SIRT1/FOXO1 signaling pathway
- in-vitro, Nor, NA
*MDA↓, *SOD↑, *SIRT1↑, *FOXO1↑, *SREBP2↓,
7565- HYP,    Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review
- Review, AD, NA
*Inflam↓, *antiOx↑, *neuroP↑, *lipid-P↓, *ROS↓, *IL1β↓, *IL6↓, *IL8↓, *TNF-α↓, *MDA↓, *BAX↓, *Casp3↓, *Catalase↑, *SOD↑, *GSH↑, *BDNF↑, *TrkB↑, *NGF↑, *BDNF↑, *NF-kB↓, *AChE↓, *H2S↑, Casp3↑, Apoptosis↑, NF-kB↓, AMPK↑, HO-1↑, MAPK↑, cl‑Casp3↑, cl‑Casp9↑, BAX↑, SOD?, Catalase↓, NRF2↓, NQO1↓, HO-1↓, Bcl-2↓, TumCCA↑, FOXO1↑, TumAuto↑, Akt↓, mTOR↓, P70S6K↓, BMP7/OP1↓, *cardioP↑, *hepatoP↑, *antiCG↑, *AntiThr↑, *Diar↓, *AntiFungal↑, *CYP2D6↓, *PDGFR-BB↓, *PDGFRB↓, *toxicity↓, *Half-Life↑,
7551- HYP,    Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1
- vitro+vivo, NSCLC, NA
TumCP↓, Apoptosis↑, FOXO1↑, CCAT1↓, TumCG↓,
1678- PBG,  5-FU,  sericin,    In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway
- in-vitro, CRC, Caco-2 - in-vivo, NA, NA
PI3K↓, Akt↓, mTOR↓, TumCP↓, Bcl-2↓, BAX↑, Casp3↑, Casp9↑, ROS↓, FOXO1↑, *toxicity∅, eff↑,
4833- Uro,    Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine
- Review, Var, NA - Review, AD, NA - Review, IBD, NA
BioAv↝, TumAuto↝, TumCG↓, TumMeta↓, ChemoSen↑, Imm↑, RadioS↑, BioAv↑, other↝, eff↓, *antiOx↓, *Inflam↓, AntiCan↓, AntiAge↑, chemoP↑, *neuroP↑, *ROS↓, *cognitive↑, *lipid-P↓, *cardioP↑, *TNF-α↓, *IL6↓, GutMicro↑, TumCCA↑, Apoptosis↑, angioG↓, NF-kB↓, PI3K↓, Akt↓, Casp↑, survivin↓, TumCP↓, cycD1/CCND1↓, cMyc↑, BAX↑, Bcl-2↓, COX2/PTGS2↓, P53↑, p38↑, *ROS↓, *SOD↑, *GPx↑, SIRT1↑, FOXO1↑, eff↑, ChemoSen↑,
4836- Uro,    Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation
- in-vitro, Var, NA
FOXO1↑, TumCG↓, PD-1↓, TIM-3↓,

Showing Research Papers: 1 to 8 of 8

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

BMP7/OP1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   HO-1↓, 1,   HO-1↑, 1,   NQO1↓, 1,   NRF2↓, 1,   ROS↓, 1,   ROS↑, 1,   SOD?, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,   XIAP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cMyc↑, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 4,   Apoptosis↑, 4,   BAX↑, 3,   Bcl-2↓, 3,   Casp↑, 1,   Casp3↑, 3,   cl‑Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 2,   cl‑Casp9↑, 1,   MAPK↑, 1,   p38↑, 1,   survivin↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,   TumAuto↝, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 2,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

FOXO1↑, 6,   GSK‐3β↑, 1,   mTOR↓, 2,   P70S6K↓, 1,   PI3K↓, 2,   TumCG↓, 3,  

Migration(tgid=13) ⓘ

CCAT1↓, 1,   TumCP↓, 3,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   Imm↑, 1,   NF-kB↓, 2,   PD-1↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

TIM-3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 2,   Dose↝, 1,   eff↓, 1,   eff↑, 2,   RadioS↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiCan↓, 1,   chemoP↑, 1,   OS↑, 1,   QoL↑, 1,   TumVol↓, 1,  
Total Targets: 64

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

antiCG↑, 1,   CYP2D6↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   lipid-P↓, 2,   MDA↓, 2,   ROS↓, 4,   SIRT3↑, 1,   SOD↑, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

H2S↑, 1,   SIRT1↑, 2,   SREBP2↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   BAX↓, 1,   Casp3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD34↑, 1,   FOXO1↑, 2,   FOXO3↑, 1,   PDGFRB↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↑, 1,   PDGFR-BB↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BDNF↑, 2,   NGF↑, 1,   TrkB↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Half-Life↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 2,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 2,   cognitive↑, 1,   hepatoP↑, 1,   neuroP↑, 2,   toxicity↓, 1,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   Diar↓, 1,  
Total Targets: 46

Scientific Paper Hit Count for: FOXO1, Forkhead box O1
2 Hyperoside
2 Urolithin
1 Alpha-Lipoic-Acid
1 Brucea javanica
1 EGCG (Epigallocatechin Gallate)
1 Propolis -bee glue
1 5-fluorouracil
1 sericin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1164  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page